Evidence map›Paper›PMID 31881017›Full record

ArticlePLoS genetics2019

The MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor.

Elizabeth A Coe, Jennifer Y Tan, Michael Shapiro, Pakavarin Louphrasitthiphol, Andrew R Bassett, Ana C Marques, Colin R Goding, Keith W Vance

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 71 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Mechanisms of apoptosis-related non-coding RNAs in ovarian cancer: a narrative review.Apoptosis : an international journal on programmed cell death · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Plumbing mysterious RNAs in "dark genome" for the conquest of human diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Review
  19. Long Non-coding RNAs and CRISPR-Cas Edition in Tumorigenesis.Advances in experimental medicine and biology · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Elizabeth A CoeDepartment of Biology and Biochemistry, University of Bath, Bath, United Kingdom.
Jennifer Y TanDepartment of Computational Biology, University of Lausanne, Lausanne, Switzerland.
Michael ShapiroDepartment of Biology and Biochemistry, University of Bath, Bath, United Kingdom.
Pakavarin LouphrasitthipholLudwig Institute for Cancer Research, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-6546-332X
Andrew R BassettWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.ORCID 0000-0003-1632-9137
Ana C MarquesDepartment of Computational Biology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-5174-8092
Colin R GodingLudwig Institute for Cancer Research, University of Oxford, Oxford, United Kingdom.
Keith W VanceDepartment of Biology and Biochemistry, University of Bath, Bath, United Kingdom.ORCID 0000-0002-3411-8213
University of Bath · GBLudwig Cancer Research · GBUniversity of Lausanne · CHWellcome Sanger Institute · GB

Funding

Tumor Assessment CoreP01CA128814 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI SMITH, JEFFREY W · 2009 to 2020
$19.1M
Biotechnology and Biological Sciences Research Council BB/N005856/1NCI NIH HHS P01 CA128814
6 · The paper itself

Abstract

The MITF and SOX10 transcription factors regulate the expression of genes important for melanoma proliferation, invasion and metastasis. Despite growing evidence of the contribution of long noncoding RNAs (lncRNAs) in cancer, including melanoma, their functions within MITF-SOX10 transcriptional programmes remain poorly investigated. Here we identify 245 candidate melanoma associated lncRNAs whose loci are co-occupied by MITF-SOX10 and that are enriched at active enhancer-like regions. Our work suggests that one of these, Disrupted In Renal Carcinoma 3 (DIRC3), may be a clinically important MITF-SOX10 regulated tumour suppressor. DIRC3 depletion in human melanoma cells leads to increased anchorage-independent growth, a hallmark of malignant transformation, whilst melanoma patients classified by low DIRC3 expression have decreased survival. DIRC3 is a nuclear lncRNA that activates expression of its neighbouring IGFBP5 tumour suppressor through modulating chromatin structure and suppressing SOX10 binding to putative regulatory elements within the DIRC3 locus. In turn, DIRC3 dependent regulation of IGFBP5 impacts the expression of genes involved in cancer associated processes and is needed for DIRC3 control of anchorage-independent growth. Our work indicates that lncRNA components of MITF-SOX10 networks are an important new class of melanoma regulators and candidate therapeutic targets that can act not only as downstream mediators of MITF-SOX10 function but as feedback regulators of MITF-SOX10 activity.

Indexed as

Cell Line, TumorCell NucleusCell ProliferationDown-RegulationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding Protein 5MelanomaMicrophthalmia-Associated Transcription FactorPrognosisRNA, Long NoncodingSequence Analysis, RNASOXE Transcription FactorsSurvival AnalysisIGFBP5 protein, humanInsulin-Like Growth Factor Binding Protein 5Microphthalmia-Associated Transcription FactorMITF protein, humanRNA, Long NoncodingSOX10 protein, humanSOXE Transcription Factors

Identifiers

PMID31881017
PMCPMC6934268
OpenAlexW2997514138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.